We further investigated this interaction using a more specific, third generation PARP inhibitor, olaparib, which has been evaluated in phase II clinical trials in the treatment of HR deficient breast and ovarian cancers [17], [19], [20]. Here, PARP1 is linked to ovarian carcinoma.